Lung cancer is a leading cause of cancer-related mortality worldwide. Despite advancements in treatment modalities, the prognosis for lung cancer patients remains poor. However, recent developments in targeted therapies have shown promising results in revolutionizing lung cancer treatment. This research article aims to provide an overview of targeted therapies and their impact on lung cancer treatment. We discuss the underlying mechanisms of targeted therapies, current targeted therapy options, challenges, and future directions in this rapidly evolving field.
Lung cancer is a complex disease with diverse molecular subtypes, and traditional treatment approaches such as surgery, chemotherapy, and radiation therapy have limitations in effectively managing advanced stages of the disease. Targeted therapies, which focus on specific molecular alterations driving cancer growth, have emerged as a breakthrough in lung cancer treatment.
Targeted therapies exploit specific molecular aberrations in cancer cells, including gene mutations, amplifications, or rearrangements. These alterations may activate signaling pathways involved in tumor growth and survival. By inhibiting these aberrant molecular targets, targeted therapies aim to disrupt tumor growth and improve patient outcomes.
HTML PDFShare this article
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report
